Title | Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder |
Publication Type | Journal Article |
Year of Publication | 2010 |
Authors | Thurstone, C, Riggs, PD, Salomonsen-Sautel, S, Mikulicn-Gilbertson, SK |
Journal | Journal of the American Academy of Child and Adolescent Psychiatry |
Volume | 49 |
Pagination | 573-582 |
Publisher | Lippincott Williams & Wilkins |
Place Published | US |
Publication Language | eng |
ISBN Number | 0890-85671527-5418 |
Accession Number | 2010-11929-006. First Author & Affiliation: Thurstone, Christian |
Keywords | adolescents, atomoxetine, Attention Deficit Disorder with Hyperactivity, attention deficit hyperactivity disorder, clinical trials, cognitive behavior therapy, Cognitive behavioral therapy, controlled trials, Drug abuse, motivational interviewing, Placebo, substance use disorder |
Abstract | Objective: To evaluate the effect of atomoxetine hydrochloride versus placebo on attention-deficit/hyperactivity disorder (ADHD) and substance use disorder (SUD) in adolescents receiving motivational interviewing/cognitive behavioral therapy (MI/CBT) for SUD. Method: This single-site, randomized, controlled trial was conducted between December 2005 and February 2008. Seventy adolescents (13 through 19 years of age) with Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) ADHD, a DSM-IV ADHD checklist score greater than or equal to 22, and at least one nontobacco SUD were recruited from the community. All subjects received 12 weeks of atomoxetine hydrochloride + MI/CBT versus placebo + MI/CBT. The main outcome measure for ADHD was self-report DSM-IV ADHD checklist score. For SUD, the main outcome was self-report number of days used nontobacco substances in the past 28 days using the Timeline Followback interview. Results: Change in ADHD scores did not differ between atomoxetine + MI/CBT and placebo + MI/CBT (F4,191 = 1.23, p = .2975). Change in days used nonnicotine substances in the last 28 days did not differ between groups (F3,100 = 2.06, p = .1103). Conclusions: There was no significant difference between the atomoxetine + MI/CBT and placebo + MI/CBT groups in ADHD or substance use change. The MI/CBT and/or a placebo effect may have contributed to a large treatment response in the placebo group. (PsycINFO Database Record (c) 2010 APA, all rights reserved) (journal abstract) |
URL | http://libproxy.unm.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-11929-006&login.asp&site=ehost-live&scope=siteChristian.Thurstone@dhha.org |